Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

DOTAP:Chol-TUSC2

Other · developed by Genprex

Phase 1/2 Most advanced trial (none active)
GNPX Developer
1 Registered trials

What is DOTAP:Chol-TUSC2?

DOTAP:Chol-TUSC2 is a liposome complex carrying the TUSC2 gene, delivered intravenously at a dose of 0.045 mg/kg on day 1 of each 21-day cycle. It is studied in lung cancer, including non-small-cell lung carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DOTAP:Cholesterol-TUSC2 Liposome Complex
Drug type
Other
Therapy area
Oncology
Developer
Genprex, Inc. (GNPX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01455389 Phase 1/2 Lung Cancer Terminated GNPX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lung Cancer

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the GNPX page.

Follow GNPX, the company behind DOTAP:Chol-TUSC2

See GNPX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GNPX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.